Literature DB >> 33247862

Hepatitis B infection and risk factors among pregnant women and their male partners in the Baby Shower Programme in Nigeria: a cross-sectional study.

Carol Talla1, Ijeoma Uchenna Itanyi2,3, Kiyomi Tsuyuki4, Nicole Stadnick5,6, Amaka Grace Ogidi2, Babayemi Oluwaseun Olakunde2,7, Dina Patel8, John Okpanachi Oko1, Gregory Aarons5,6, Chima Ariel Onoka2,3, Echezona Edozie Ezeanolue2,8.   

Abstract

OBJECTIVES: To determine the population prevalence and determinants of hepatitis B (Hep B) status, and status discordance, among pregnant women and their male partners in Nigeria.
METHODS: Cross-sectional study assessing the seroprevalence of Hep B virus in a cohort of 16 920 pregnant women and their male partners in northcentral Nigeria. Rapid HBsAg antibody test was used for Hep B diagnosis. Demographic, socio-economic and behavioural information was collected through interviewer-administered questionnaires and evaluated as determinants of Hep B status and couple status discordance using logistic regression.
RESULTS: Of 16 920 participants who had a Hep B test result, 6750 couples and 1316 discordant couples were identified. The prevalence of Hep B among all participants was 10.9%, with lower prevalence among pregnant women (10.2%) than their male partners (11.9%), P < 0.001. The prevalence of Hep B sero-discordance among couples was 19.5% (1316/6750). Younger age, prior Hep B testing and a prior positive Hep B test increased the odds of Hep B infection while being a woman decreased the odds of Hep B among all participants, and among couples. Furthermore, polygamy (adjusted odds ratio [AOR]: 1.49, 95% confidence interval [CI]: 1.19-1.87), prior Hep B testing (AOR: 2.38, 95% CI: 1.14-4.97) and a prior positive Hep B test result were significant determinants of status discordance among the participating couples.
CONCLUSION: The prevalence of Hep B among pregnant women and their male partners in northcentral Nigeria is high. A large-scale intervention is required to reduce Hep B prevalence in this setting.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  Hepatitis B; Nigeria; pregnant women; prevalence; sexual partners

Mesh:

Year:  2020        PMID: 33247862      PMCID: PMC7925376          DOI: 10.1111/tmi.13531

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  39 in total

1.  Seroprevalence of HBV, HCV, and HIV and Associated Risk Factors Among Apparently Healthy Pregnant Women in Anyigba, Nigeria.

Authors:  Cornelius Arome Omatola; Christiana Lawal; Deborah Omolara Omosayin; Martin-Luther Oseni Okolo; David Moses Adaji; Charles Kehinde Mofolorunsho; Kizito Emeje Bello
Journal:  Viral Immunol       Date:  2019-04-24       Impact factor: 2.257

Review 2.  The emergence of hepatitis B as a sexually transmitted disease.

Authors:  M J Alter; H S Margolis
Journal:  Med Clin North Am       Date:  1990-11       Impact factor: 5.456

3.  Hepatitis B and hepatocellular carcinoma.

Authors:  Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

4.  Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.

Authors:  R P Beasley; L Y Hwang; G C Lee; C C Lan; C H Roan; F Y Huang; C L Chen
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

5.  Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission.

Authors:  C E Stevens; P E Taylor; M J Tong; P T Toy; G N Vyas; P V Nair; J Y Weissman; S Krugman
Journal:  JAMA       Date:  1987-05-15       Impact factor: 56.272

6.  Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial.

Authors:  R P Beasley; L Y Hwang; C E Stevens; C C Lin; F J Hsieh; K Y Wang; T S Sun; W Szmuness
Journal:  Hepatology       Date:  1983 Mar-Apr       Impact factor: 17.425

7.  AASLD guidelines for treatment of chronic hepatitis B.

Authors:  Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

Review 8.  Hepatitis B: evolving epidemiology and implications for control.

Authors:  H S Margolis; M J Alter; S C Hadler
Journal:  Semin Liver Dis       Date:  1991-05       Impact factor: 6.115

9.  What do You Need to Get Male Partners of Pregnant Women Tested for HIV in Resource Limited Settings? The Baby Shower Cluster Randomized Trial.

Authors:  Echezona E Ezeanolue; Michael C Obiefune; Wei Yang; Chinenye O Ezeanolue; Jennifer Pharr; Alice Osuji; Amaka G Ogidi; Aaron T Hunt; Dina Patel; Gbenga Ogedegbe; John E Ehiri
Journal:  AIDS Behav       Date:  2017-02

10.  Comparative effectiveness of congregation- versus clinic-based approach to prevention of mother-to-child HIV transmission: study protocol for a cluster randomized controlled trial.

Authors:  Echezona E Ezeanolue; Michael C Obiefune; Wei Yang; Stephen K Obaro; Chinenye O Ezeanolue; Gbenga G Ogedegbe
Journal:  Implement Sci       Date:  2013-06-08       Impact factor: 7.327

View more
  3 in total

1.  A systematic review and meta-analysis of the prevalence of hepatitis B virus infection among pregnant women in Nigeria.

Authors:  Babayemi O Olakunde; Daniel A Adeyinka; Olubunmi A Olakunde; Olalekan A Uthman; Florence O Bada; Yvonne A Nartey; Dorcas Obiri-Yeboah; Elijah Paintsil; Echezona E Ezeanolue
Journal:  PLoS One       Date:  2021-10-29       Impact factor: 3.240

2.  Occult Hepatitis B Virus Infection and Its Risks of Cryptic Transmission in Southern Ethiopia.

Authors:  Gizachew Beykaso; Andargachew Mulu; Mirutse Giday; Nega Berhe; Markos Selamu; Dawit Hailu; Tilahun Teklehaymanot
Journal:  Infect Drug Resist       Date:  2022-02-24       Impact factor: 4.003

3.  Building a national framework for multicentre research and clinical trials: experience from the Nigeria Implementation Science Alliance.

Authors:  John Olajide Olawepo; Echezona Edozie Ezeanolue; Adanma Ekenna; Olabanjo O Ogunsola; Ijeoma Uchenna Itanyi; Elima Jedy-Agba; Emmanuel Egbo; Chukwudi Onwuchekwa; Alexandra Ezeonu; Abiola Ajibola; Babayemi O Olakunde; Omololuoye Majekodunmi; Amaka G Ogidi; JohnBosco Chukwuorji; Nwamaka Lasebikan; Patrick Dakum; Prosper Okonkwo; Bolanle Oyeledun; John Oko; Hadiza Khamofu; Akudo Ikpeazu; Uchechukwu Emmanuel Nwokwu; Gambo Aliyu; Oladapo Shittu; Anne F Rositch; Byron J Powell; Donaldson F Conserve; Gregory A Aarons; Ayodotun Olutola
Journal:  BMJ Glob Health       Date:  2022-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.